Raphaël Heinzer, ERS 2018 – Obstructive sleep apnoea in Europe
Raphaël Heinzer (University Hospital of Lausanne, Lausanne, Switzerland) talks to us about the prevalence of obstructive sleep apnoea (OSA) in Europe, the importance of current clinical pathways for its diagnosis and treatment, and provides expert advice on identifying signs and symptoms, as well as what to do for patients at high risk.
1. You recently co-authored a paper looking at the prevalence of obstructive sleep apnoea (OSA) in Europe, could you please tell us about the study and your findings? (0:11)
2. How will current clinical pathways handle the identification, diagnosis and treatment of the estimated 175 million Europeans with OSA? (0:48)
3. There have not been many OSA prevalence studies conducted in the past, why do you think that is? (1:08)
4. What is the impact of untreated OSA? (1:35)
5. For the medical community not familiar with OSA, what are the signs and symptoms that they should look for in assessing if their patient may have OSA? If they feel that their patient is at high risk for OSA, what should they do? (2:07)
Speaker disclosure: Raphaël Heinzer is an advisory board member for NightBalance and Dream devices and receives speaker fees from Philips.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018, supported by ResMed.
Share this Video
Related Videos In Sleep Related Breathing Disorders
Margaret Pisani, CHEST 2022: Highlights and networking opportunities
CHEST 2022 took place between October 16-19 in Nashville, TN, we interviewed editorial board member Prof. Margaret Pisani (Yale School of Medicine. New Haven, CT, USA) around her personal congress highlights and the networking opportunities which were available on site. Questions What CHEST presentations had the greatest impact this year and what were your personal […]
John Harsh, CHEST 2022: Long term safety of FT218 in the treatment of narcolepsy
Once-nightly sodium oxybate (FT218) is currently being investigated in the open label phase 3 study RESTORE (NCT04451668) for the treatment of narcolepsy. We caught up with Prof. John Harsh (University of Colorado Boulder, Boulder, CO, USA) to discuss the aims, design, inclusion criteria and interim findings of the RESTORE study. The abstract ‘LONG-TERM SAFETY OF […]
Joerg Steier, ATS 2022: the Delphi Consensus Statements on Excessive Daytime Sleepiness in Obstructive Sleep Apnea
It was a pleasure to talk with Professor Joerg Steier (King’s College London, London, UK) around the development of the Delphi Consensus Statements on the diagnosis and management of excessive daytime sleepiness in obstructive sleep apnea and how these statements will help identify and address the unmet needs. The abstract ‘Development of Delphi Consensus Statements […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!